Site Activity
This page provides a monthly listing of publication activity on the Medical Policy Portal including Policy Notifications, New Policies, Updated Policies, Coding Updates, Reissued Policies, and Archived Policies. To view publication activity from prior months, select Past Site Activity.

Past Site Activity
 
                                                                                                        

Notifications
The following Independence Blue Cross Medicare Advantage policies have been posted prior to their effective date.
MA00.045c, Incident To and Non-Incident To Services Performed by Certified Registered Nurse Practitioners (CRNPs) and Physician Assistants (PAs)
Notification: 03/01/2019 | Effective: 06/01/2019 | Posted: 03/01/2019
Type of policy change: General Description, Guidelines, or Informational Update

MA08.036c, Alglucosidase alfa (e.g., Lumizyme®)
Notification: 03/05/2019 | Effective: 06/03/2019 | Posted: 03/05/2019
Type of policy change: Medical Necessity Criteria; General Description, Guidelines, or Informational Update

MA08.034d, Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme®, Elaprase®, Vimizim®, Naglazyme®, Mepsevii™, etc.)
Notification: 03/05/2019 | Effective: 06/03/2019 | Posted: 03/05/2019
Type of policy change: Medical Necessity Criteria; General Description, Guidelines, or Informational Update

MA08.023b, Enzyme Replacement for the Treatment of Gaucher's Disease
Notification: 03/05/2019 | Effective: 06/03/2019 | Posted: 03/05/2019
Type of policy change: Medical Necessity Criteria; Medical Coding; General Description, Guidelines, or Informational Update

MA08.033b, Agalsidase beta (Fabrazyme®)
Notification: 03/05/2019 | Effective: 06/03/2019 | Posted: 03/05/2019
Type of policy change: Medical Necessity Criteria; General Description, Guidelines, or Informational Update

MA08.089c, Cerliponase alfa (Brineura®)
Notification: 03/05/2019 | Effective: 06/03/2019 | Posted: 03/05/2019
Type of policy change: Medical Necessity Criteria

MA08.022g, Rituximab (Rituxan®) Infusion and Related Biosimilars, and Rituximab/Hyaluronidase Human for Subcutaneous Injection (Rituxan Hycela®)
Notification: 03/19/2019 | Effective: 06/17/2019 | Posted: 03/19/2019
Type of policy change: Coverage and/or Reimbursement Position; Medical Necessity Criteria; Medical Coding; General Description, Guidelines, or Informational Update


Updated Policies
The following Medicare Advantage policies have been reviewed and updated to communicate current coverage and/or reimbursement positions, reporting requirements, and other procedures for doing business with Independence Blue Cross.
MA09.020h, Radiation Therapy Services
Notification: 11/30/2018 | Effective: 03/01/2019 | Posted: 03/01/2019
Type of policy change: General Description, Guidelines, or Informational Update

MA07.016b, Intravenous Chelation Therapy
Effective: 03/04/2019 | Posted: 03/04/2019
Type of policy change: Medical Necessity Criteria; Medical Coding; General Description, Guidelines, or Informational Update

MA08.091c, Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®)
Effective: 03/11/2019 | Posted: 03/11/2019
Type of policy change: Medical Necessity Criteria; Medical Coding; General Description, Guidelines, or Informational Update

MA07.055c, Allergy Immunotherapy
Effective: 03/11/2019 | Posted: 03/11/2019
Type of policy change: General Description, Guidelines, or Informational Update

MA08.056c, Eribulin Mesylate (Halaven®)
Notification: 12/26/2018 | Effective: 03/25/2019 | Posted: 03/25/2019
Type of policy change: Coverage and/or Reimbursement Position

MA06.002b, In Vitro Allergy Testing
Notification: 02/22/2019 | Effective: 03/25/2019 | Posted: 03/25/2019
Type of policy change: Medical Necessity Criteria; General Description, Guidelines, or Informational Update


Reissue Policies
The following Medicare Advantage policies have been reviewed, and no substantive changes were made.
MA05.064, Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT)
Reissue Effective: 03/13/2019 | Reissue Posted: 03/14/2019

MA05.004c, Pneumatic Compression Therapy Devices
Reissue Effective: 03/13/2019 | Reissue Posted: 03/14/2019

MA05.022, Home-Use Light Box for the Treatment of Seasonal Affective Disorder (SAD)
Reissue Effective: 03/13/2019 | Reissue Posted: 03/14/2019

MA07.036b, Low-Level Laser Therapy
Reissue Effective: 03/13/2019 | Reissue Posted: 03/14/2019

MA05.003c, Speech and Non-Speech Generating Devices
Reissue Effective: 03/13/2019 | Reissue Posted: 03/14/2019

MA08.070c, Golimumab (Simponi® Aria™) Intravenous (IV) Injection
Reissue Effective: 03/14/2019 | Reissue Posted: 03/14/2019

MA08.006e, Siltuximab (Sylvant®)
Reissue Effective: 03/14/2019 | Reissue Posted: 03/14/2019

MA08.028c, Abatacept (Orencia®) for Injection for Intravenous Use
Reissue Effective: 03/14/2019 | Reissue Posted: 03/14/2019

MA08.098a, Tildrakizumab-asmn (Ilumya™)
Reissue Effective: 03/14/2019 | Reissue Posted: 03/14/2019

MA08.057a, Belimumab (Benlysta®) for Intravenous Use
Reissue Effective: 03/27/2019 | Reissue Posted: 03/28/2019

MA05.043a, Mechanical Stretching Devices for the Treatment of Joint Stiffness or Contractures
Reissue Effective: 03/27/2019 | Reissue Posted: 03/28/2019

MA08.061, Belatacept (Nulojix®)
Reissue Effective: 03/27/2019 | Reissue Posted: 03/28/2019

MA05.054d, Urological Supplies
Reissue Effective: 03/27/2019 | Reissue Posted: 03/28/2019

MA08.074, Deoxycholic Acid (Kybella™)
Reissue Effective: 03/28/2019 | Reissue Posted: 03/28/2019

MA07.025d, Intrauterine Systems (IUSs) (e.g., Mirena®, Skyla®, Liletta®, Kyleena®)
Reissue Effective: 03/27/2019 | Reissue Posted: 03/28/2019

MA00.001a, Obsolete or Unreliable Diagnostic Tests and Medical Services
Reissue Effective: 03/27/2019 | Reissue Posted: 03/28/2019










Connect with Us        


© 2017 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.